New biologics in the management of Crohn’s disease: focus on certolizumab pegol
Elisabetta Colombo1, Fabrizio Bossa1, Anna Latiano2, Orazio Palmieri2, Angelo Andriulli1,2, Vito Annese2,31Unit of Gastroenterology, 2Laboratory of Genetic Research, 3Unit of Endoscopy, Department of Medical Sciences, IRCCS-CSS Hospital, San Giovanni Rotondo, ItalyAbstract: Crohn’s dis...
Main Authors: | Elisabetta Colombo, Fabrizio Bossa, Anna Latiano, Orazio Palmieri, Angelo Andriulli, Vito Annese |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-06-01
|
Series: | Clinical and Experimental Gastroenterology |
Online Access: | http://www.dovepress.com/new-biologics-in-the-management-of-crohnrsquos-disease-focus-on-certol-a3287 |
Similar Items
-
Certolizumab pegol in treatment of Crohn's disease with perianal lesions
by: I L Khalif, et al.
Published: (2018-04-01) -
Certolizumab pegol in treatment of Crohn's disease with perianal lesions
by: I.L. Khalif, et al.
Published: (2018-04-01) -
Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practice
by: O V Knyazev, et al.
Published: (2018-06-01) -
Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn's Disease
by: Wojciech Blonski, et al.
Published: (2012-01-01) -
Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn's Disease
by: Wojciech Blonski, et al.
Published: (2012-04-01)